News

FDA Hosts Antimicrobial Drug Advisory Committee Meeting to Discuss NDA for Tuberculosis

**Update: The US FDA Antimicrobial Drug Advisory Committee voted in favor of the NDA 14 to 4 on June 6th, 2019**

The United States Food & Drug Administration (FDA) will host the Antimicrobial Drug Advisory Committee on Thursday, June 6th to discuss the new drug application (NDA) involving new chemical entity, pretomanid, in combination with bedaquiline and linezolid in an all-oral 6-month defined regimen for adults with extensively drug resistant (XDR) tuberculosis or treatment-intolerant or non-responsive multidrug resistant (MDR) tuberculosis submitted by TB Alliance. 

The FDA will provide a live web broadcast of the meeting which will take place from 8AM to 4PM. A link to the broadcast can be found here: webcast.

A link to the agenda of the meeting can be found here: June 6th, 2019 Antimicrobial Drug Advisory Committee Meeting Agenda.

Further materials relating to the NDA and meeting can be found here: meeting materials.

For more information about Pretomanid, please visit the WGND compound page on Pretomanid where you can view links to clinical trials and regimens involving Pretomanid. 

Additional links: 

TB Alliance's Press Release

Reuters article

More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...